Comparing stem cell transplant to antibody therapies for relapsing MS

This trial is testing whether autologous hematopoietic stem cell transplantation—a procedure where your own blood-forming stem cells are removed, your immune system is reset, and the cells are returned—works better than two commonly used antibody medications (alemtuzumab and ocrelizumab or ofatumumab) for relapsing-remitting multiple sclerosis. Researchers will carefully track disease markers in your blood and monitor how well each treatment prevents your MS from progressing to a more advanced stage.

Most current MS treatments focus on stopping relapses but may not be as effective at preventing long-term disability progression. This medication takes a different approach by essentially 'rebooting' your immune system, and early evidence suggests it may offer better long-term protection against progression compared to the standard antibody therapies.